Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Getting through the matrix

19.05.2003


MGH research suggests strategies for improving drug delivery to cancer cells



The best cancer drugs in the world are not much good if they cannot get to tumor cells. That problem has been challenging cancer physicians and researchers for years because the physical structure of many tumors can prevent anticancer agents from reaching their targets. In a study appearing in the June issue of Nature Medicine, researchers from Massachusetts General Hospital (MGH) describe a new technique for assessing the permeability of tumors and a promising new way of improving tumors’ accessibility to drugs. The report is receiving advance online publication on the journal’s website at http://www.nature.com/nm/.

"We’ve known for a long time that many cancer drugs work very well on cells, but not so well in patients," says Rakesh Jain, PhD, director of the Steele Laboratory for Tumor Biology at MGH, senior author of the study. "As we have improved the understanding of tumor physiology, we have found that a significant portion of a tumor is made up of an extracellular matrix that acts as a barrier, keeping drugs away from tumor cells."


This matrix is largely made up of the connective tissue collagen. To determine the structure and content of collagen in different tumor types and to assess its effect on a tumor’s permeability, Jain’s team used a new imaging technique called second-harmonic generation (SHG), a non-invasive way of measuring an optical signal released by certain molecular structures. The researchers first showed that SHG can distinguish among types of connective tissue molecules and can specifically image the structure and density of collagen fibers.

By imaging tumors that had been implanted in mice, Jain’s team was able to produce high-definition 3-D images that revealed the amount and form of collagen. Studying three types of tumors known to have different relative collagen contents, they showed that SHG could accurately measure collagen levels that correlated with measurements of tumor permeability. This result suggests that SHG could allow analysis of the structure and content of a tumor’s collagen to help with treatment planning.

To test whether SHG could measure collagen modification, the researchers first applied the enzyme collagenase, which breaks down collagen, directly to mouse tumors. Images taken after collagenase application showed significant changes in the SHG images. However, because collagen is an important part of the body’s overall structure, collagenase would not be a useful treatment adjunct since its effect could spread far beyond the tumor itself.

In their search for an agent to selectively break down tumor-matrix collagen, the research team turned to a hormone called relaxin. Naturally produced in pregnant females, relaxin increases production of enzymes associated with dilation of the cervix and other processes needed for birth preparation. Clinical trials for other potential uses of relaxin have found only minor side effects in humans.

The researchers used intravenous pumps to deliver relaxin into the bloodstream of mice with implanted human tumors and then used SHG to image the tumors over a 12-day period. They also imaged the tumors of a control group that did not receive relaxin. While the amount of collagen in the relaxin-treated tumors was similar to that seen in the control group at the end of the study period, in the relaxin-treated mice the collagen fibers had broken down and were measurably shorter. When the researchers used probe molecules to measure the tumors’ permeability, the results indicated that the relaxin-treated matrix tissue was looser and less of an obstacle to penetration.

"We have already started animal studies to measure whether relaxin can improve actual response to chemotherapy drugs," says Jain, who is A.W. Cook Professor of Tumor Biology at Harvard Medical School. "If those results are positive, the fact that relaxin is so safe means we could move relatively quickly into human clinical trials."

A key collaborator in this research is Brian Seed, PhD, of the MGH Department of Molecular Biology. Other authors of the report are Edward Brown, PhD, of MGH and Trevor McKee, BSc, of Massachusetts Institute of Technology, co-first authors; Emmanuelle diTomaso, PhD, and Yves Boucher, PhD, also of MGH; and Alain Pluen, PhD, of the University of Manchester in the United Kingdom. The research was supported by grants from the National Cancer Institute.


###
Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $350 million and major research centers in AIDS, cardiovascular research, cancer, cutaneous biology, neurodegenerative disorders, transplantation biology and photomedicine. In 1994, MGH and Brigham and Women’s Hospital formed Partners HealthCare System, an integrated health care delivery system comprising the two academic medical centers, specialty and community hospitals, a network of physician groups, and nonacute and home health services.


Sue McGreevey | EurekAlert!
Further information:
http://www.mgh.harvard.edu/

More articles from Health and Medicine:

nachricht New leukemia treatment offers hope
23.09.2016 | King Abdullah University of Science and Technology

nachricht Alzheimer’s: Cellular Mechanism Provides Explanation Model for Declining Memory Performance
21.09.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

Im Focus: Complex hardmetal tools out of the 3D printer

For the first time, Fraunhofer IKTS shows additively manufactured hardmetal tools at WorldPM 2016 in Hamburg. Mechanical, chemical as well as a high heat resistance and extreme hardness are required from tools that are used in mechanical and automotive engineering or in plastics and building materials industry. Researchers at the Fraunhofer Institute for Ceramic Technologies and Systems IKTS in Dresden managed the production of complex hardmetal tools via 3D printing in a quality that are in no way inferior to conventionally produced high-performance tools.

Fraunhofer IKTS counts decades of proven expertise in the development of hardmetals. To date, reliable cutting, drilling, pressing and stamping tools made of...

Im Focus: Launch of New Industry Working Group for Process Control in Laser Material Processing

At AKL’16, the International Laser Technology Congress held in May this year, interest in the topic of process control was greater than expected. Appropriately, the event was also used to launch the Industry Working Group for Process Control in Laser Material Processing. The group provides a forum for representatives from industry and research to initiate pre-competitive projects and discuss issues such as standards, potential cost savings and feasibility.

In the age of industry 4.0, laser technology is firmly established within manufacturing. A wide variety of laser techniques – from USP ablation and additive...

Im Focus: New laser joining technologies at ‘K 2016’ trade fair

Every three years, the plastics industry gathers at K, the international trade fair for plastics and rubber in Düsseldorf. The Fraunhofer Institute for Laser Technology ILT will also be attending again and presenting many innovative technologies, such as for joining plastics and metals using ultrashort pulse lasers. From October 19 to 26, you can find the Fraunhofer ILT at the joint Fraunhofer booth SC01 in Hall 7.

K is the world’s largest trade fair for the plastics and rubber industry. As in previous years, the organizers are expecting 3,000 exhibitors and more than...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Experts from industry and academia discuss the future mobile telecommunications standard 5G

23.09.2016 | Event News

ICPE in Graz for the seventh time

20.09.2016 | Event News

Using mathematical models to understand our brain

16.09.2016 | Event News

 
Latest News

Chains of nanogold – forged with atomic precision

23.09.2016 | Life Sciences

New leukemia treatment offers hope

23.09.2016 | Health and Medicine

Self-assembled nanostructures hit their target

23.09.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>